JP6673915B2 - １型肝腎症候群患者の治療方法 - Google Patents

１型肝腎症候群患者の治療方法 Download PDF

Info

Publication number
JP6673915B2
JP6673915B2 JP2017521988A JP2017521988A JP6673915B2 JP 6673915 B2 JP6673915 B2 JP 6673915B2 JP 2017521988 A JP2017521988 A JP 2017521988A JP 2017521988 A JP2017521988 A JP 2017521988A JP 6673915 B2 JP6673915 B2 JP 6673915B2
Authority
JP
Japan
Prior art keywords
patient
terlipressin
treatment
criteria
sirs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017521988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534618A (ja
JP2017534618A5 (OSRAM
Inventor
クーラム ジャミル，
クーラム ジャミル，
スティーブン クリス パッパス，
スティーブン クリス パッパス，
ジム ポテンジアーノ，
ジム ポテンジアーノ，
Original Assignee
マリンクロット ホスピタル プロダクツ アイピー リミテッド
マリンクロット ホスピタル プロダクツ アイピー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マリンクロット ホスピタル プロダクツ アイピー リミテッド, マリンクロット ホスピタル プロダクツ アイピー リミテッド filed Critical マリンクロット ホスピタル プロダクツ アイピー リミテッド
Publication of JP2017534618A publication Critical patent/JP2017534618A/ja
Publication of JP2017534618A5 publication Critical patent/JP2017534618A5/ja
Priority to JP2019155678A priority Critical patent/JP6989571B2/ja
Application granted granted Critical
Publication of JP6673915B2 publication Critical patent/JP6673915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1024—Counting particles by non-optical means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
JP2017521988A 2014-10-24 2015-10-22 １型肝腎症候群患者の治療方法 Active JP6673915B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019155678A JP6989571B2 (ja) 2014-10-24 2019-08-28 １型肝腎症候群患者の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462068357P 2014-10-24 2014-10-24
US62/068,357 2014-10-24
US201562151384P 2015-04-22 2015-04-22
US62/151,384 2015-04-22
PCT/US2015/056861 WO2016065117A1 (en) 2014-10-24 2015-10-22 Method of treating patients with hepatorenal syndrome type 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019155678A Division JP6989571B2 (ja) 2014-10-24 2019-08-28 １型肝腎症候群患者の治療方法

Publications (3)

Publication Number Publication Date
JP2017534618A JP2017534618A (ja) 2017-11-24
JP2017534618A5 JP2017534618A5 (OSRAM) 2018-09-27
JP6673915B2 true JP6673915B2 (ja) 2020-03-25

Family

ID=54478246

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017521988A Active JP6673915B2 (ja) 2014-10-24 2015-10-22 １型肝腎症候群患者の治療方法
JP2019155678A Active JP6989571B2 (ja) 2014-10-24 2019-08-28 １型肝腎症候群患者の治療方法
JP2021102221A Active JP7346494B2 (ja) 2014-10-24 2021-06-21 １型肝腎症候群患者の治療方法
JP2022146052A Withdrawn JP2022171795A (ja) 2014-10-24 2022-09-14 １型肝腎症候群患者の治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019155678A Active JP6989571B2 (ja) 2014-10-24 2019-08-28 １型肝腎症候群患者の治療方法
JP2021102221A Active JP7346494B2 (ja) 2014-10-24 2021-06-21 １型肝腎症候群患者の治療方法
JP2022146052A Withdrawn JP2022171795A (ja) 2014-10-24 2022-09-14 １型肝腎症候群患者の治療方法

Country Status (15)

Country Link
US (2) US10335452B2 (OSRAM)
EP (3) EP3978074B1 (OSRAM)
JP (4) JP6673915B2 (OSRAM)
CN (2) CN107206049B (OSRAM)
AU (1) AU2015335855A1 (OSRAM)
CA (1) CA2965325A1 (OSRAM)
DK (2) DK3978074T3 (OSRAM)
ES (2) ES2987577T3 (OSRAM)
FI (1) FI3978074T3 (OSRAM)
HR (1) HRP20220225T1 (OSRAM)
HU (1) HUE058066T2 (OSRAM)
PL (2) PL3978074T3 (OSRAM)
PT (2) PT3978074T (OSRAM)
SI (1) SI3209317T1 (OSRAM)
WO (1) WO2016065117A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3058497T3 (en) 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
US20200046798A1 (en) * 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
CN107206049B (zh) * 2014-10-24 2021-12-07 马林克罗特医疗产品知识产权公司 治疗患1型肝肾综合征的患者的方法
US20210290725A1 (en) * 2014-10-24 2021-09-23 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1
IL313083A (en) 2016-10-21 2024-07-01 Amryt Endo Inc Terlipressin compositions and their methods of use
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN110251469B (zh) * 2019-07-31 2021-11-09 南京康舟医药科技有限公司 一种醋酸特利加压素制剂及其制备方法
KR20220092868A (ko) * 2019-10-30 2022-07-04 말린크로트 호스피탈 프로덕츠 아이피 언리미티드 캄파니 제1형 간신증후군 및 낮은 평균 동맥압 환자의 치료 방법
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GB0617581D0 (en) * 2006-09-07 2006-10-18 Ucl Business Plc Biomarkers for assessing liver function
WO2008112563A1 (en) * 2007-03-09 2008-09-18 Flowmedica, Inc. Acute kidney injury treatment systems and methods
US9050286B2 (en) 2007-08-14 2015-06-09 Ferring B.V. Use of peptidic vasopression receptor agonists
JP5752600B2 (ja) * 2008-11-10 2015-07-22 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法
US20100260739A1 (en) 2009-03-09 2010-10-14 Bioatla, Llc Mirac Proteins
EP2440200B8 (en) 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
AU2011279144A1 (en) * 2010-07-14 2013-01-24 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
CN103254295A (zh) * 2013-05-31 2013-08-21 青岛国大生物制药股份有限公司 特利加压素的制备方法
CN107206049B (zh) * 2014-10-24 2021-12-07 马林克罗特医疗产品知识产权公司 治疗患1型肝肾综合征的患者的方法
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
PL3978074T3 (pl) 2024-08-12
JP2017534618A (ja) 2017-11-24
ES2904492T3 (es) 2022-04-05
ES2987577T3 (es) 2024-11-15
DK3209317T3 (da) 2022-02-07
EP3209317A1 (en) 2017-08-30
CN114028536A (zh) 2022-02-11
WO2016065117A1 (en) 2016-04-28
JP6989571B2 (ja) 2022-01-05
DK3978074T3 (da) 2024-05-13
EP3209317B1 (en) 2021-12-08
JP2022171795A (ja) 2022-11-11
CN107206049A (zh) 2017-09-26
JP7346494B2 (ja) 2023-09-19
EP3978074A1 (en) 2022-04-06
HRP20220225T1 (hr) 2022-04-29
CA2965325A1 (en) 2016-04-28
AU2015335855A1 (en) 2017-05-18
US10335452B2 (en) 2019-07-02
EP3978074B1 (en) 2024-03-06
JP2021155433A (ja) 2021-10-07
CN114028536B (zh) 2024-07-09
PL3209317T3 (pl) 2022-05-23
JP2019199485A (ja) 2019-11-21
PT3978074T (pt) 2024-05-13
FI3978074T3 (fi) 2024-05-20
EP3981420A1 (en) 2022-04-13
US20160113994A1 (en) 2016-04-28
SI3209317T1 (sl) 2022-05-31
HUE058066T2 (hu) 2022-06-28
PT3209317T (pt) 2022-01-19
CN107206049B (zh) 2021-12-07
US20190328831A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7346494B2 (ja) １型肝腎症候群患者の治療方法
US20240366710A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20220143132A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20250276033A1 (en) Compositions for improving kidney function in patients with hepatorenal syndrome
US20200237856A1 (en) Method of treating patients with hepatorenal syndrome type 1
JP2024522283A (ja) １型肝腎症候群を有する患者を治療する方法
JP2023500654A (ja) １型肝腎症候群及び低い平均動脈圧を有する患者を治療する方法
Takeuchi et al. Recurrent Vasovagal Syncope in a Patient Receiving Pembrolizumab for Postoperative Pulmonary Metastases of Laryngeal Cancer: A Case Report
Picardi et al. GH-resistance in different stages of chronic liver disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180814

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200305

R150 Certificate of patent or registration of utility model

Ref document number: 6673915

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250